

1 **Diagnostic Performance of Rapid Antigen Testing for SARS-CoV-2:**

2 **The COVid-19 AntiGen (COVAG) Extension study**

3 **Christoph Wertenauer^{1*,2,3}, Alexander Dressel⁴, Eberhard Wieland⁵, Hans-Jörg Wertenauer²,**
4 **Helmine Braitmaier⁵, Anna Straub⁵, Nicholas Lützner⁵, Winfried März^{1,6,7}**

5 1 Medical Clinic V, Medical Faculty Mannheim, University of Heidelberg, Mannheim,
6 Germany

7 2 Hausärzte am Schillerplatz, Stuttgart, Germany

8 3 SYNLAB Holding Deutschland GmbH, Augsburg, Germany

9 4 Dr. Dressel Consulting, Mannheim, Germany

10 5 SYNLAB Medical Care Center Leinfelden-Echterdingen GmbH, Leinfelden-Echterdingen,
11 Germany

12 6 SYNLAB Academy, SYNLAB Holding Deutschland GmbH, Mannheim, Germany

13 7 Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of
14 Graz, Graz, Austria

15 *** Correspondence:**

16 Christoph Wertenauer

17 christoph.wertenauer@uni-heidelberg.de

18 V. Medizinische Klinik

19 Universitätsklinikum Mannheim GmbH

20 Theodor-Kutzer-Ufer 1-3

21 68167 Mannheim

22

23 Word count of manuscript: 6900

24 Number of figures: 5

25 Number of tables: 4

26 Number of supplementary tables: 2

27

- 28 **Keywords: SARS-CoV-2, Rapid antigen detection test, antigen test, variants, Omicron, Delta,**
29 **Covid-19, diagnostic.**

30 Abstract

31 Background: Rapid antigen tests (RATs) for SARS-CoV-2 have been used to combat the still
32 ongoing Covid-19 pandemic. This study is the extension of the COVAG study originally performed
33 from February 1 to March 31, 2021. We compared two RATs, the Panbio COVID-19 Ag Rapid Test
34 (Abbott) and the SD Biosensor Q SARS-CoV-2 Rapid Antigen Test (Roche), against RT-PCR on the
35 foil of new variants.

36 Methods: We included 888 all-comers at a diagnostic center between October 20, 2021, and March
37 18, 2022. RT-PCR-positive samples with a Ct value ≤ 32 were examined for SARS-CoV-2 variants.

38 Findings: The sensitivity of the Abbott-RAT and Roche-RAT were 65% and 67%, respectively. For
39 both RATs, lower Ct values were significantly correlated with higher sensitivity. For samples with Ct
40 values ≤ 25 , the sensitivities of the Roche-RAT and of the Abbott-RAT were 96% and 95%, for Ct
41 values 25-30 both were 19%, and for Ct values ≥ 30 they were 6% and 2%, respectively. The RATs
42 had substantially higher sensitivities in symptomatic than asymptomatic participants (76, 77%, vs.
43 29, 31%, for Abbott-RAT, Roche-RAT, respectively) and in participants referred to testing by their
44 primary care physician (84%, 85%) compared to participants who sought testing due to referral by
45 the health department (55%, 58%) or a warning by the Corona-Warn-App (49%, 49%). In persons
46 with self-reported previous Covid-19 sensitivities were markedly lower than in patients without
47 previous Covid-19: 27% vs. 75% for Roche-RAT and 27% vs. 73% for Abbott-RAT. Depending on
48 the vaccination status, the sensitivity of the RATs is 67.6%, 61.5% and 70.6% for non-vaccinated,
49 vaccinated and boosted participants, respectively. For the considered subpopulation of 888
50 participants, we find no significant correlation between vaccination status and sensitivity.

51 The Omicron variant was detected with a sensitivity of 94% and 92%, the delta variant with a
52 sensitivity of 80% and 80% for Abbott-RAT and Roche-RAT, respectively. This difference is
53 attributable to the lower Ct values of the Omicron samples compared to the Delta samples. When
54 adjusted for the Ct value, a multivariate logistic regression did not show a significant difference
55 between Omicron and Delta. In terms of sensitivity, we found no significant difference between the
56 wild-type and the Omicron and Delta variants, but a significantly lower sensitivity to the alpha
57 variant compared to the other variants.

58 For a Ct value ≤ 25 the sensitivities were 95.2% and 96.0% for the Abbott-RAT and the Roche-RAT,
59 respectively (Table 4). For a Ct value of 25-30 both RATs had a sensitivity of 18.8%. For a Ct value

60 of 30-32, the sensitivities were 0.0% and 7.1% respectively, for Ct values ≥ 32 the sensitivities were
61 3.0% and 6.0% for Abbott-RAT and Roche-RAT, respectively.

62 The specificities were >99% overall.

63 Interpretation: The sensitivity of the RATs for asymptomatic carriers is unsatisfactory questioning
64 their use for screening. When used in symptomatic patients or when requested by a primary care
65 physician the sensitivities were higher. Our study does not suggest that the vaccination status
66 influences the sensitivity of RATs.

67 1. Introduction

68 Severe acute respiratory syndrome Coronavirus type 2 (SARS-CoV-2) is the causative agent of
69 Coronavirus disease 19 (Covid-19). Covid-19 emerged in late 2019, quickly spread around the world
70 and was declared a global pandemic on March 11, 2021, by the World Health Organization (WHO).¹
71 Since its emergence multiple SARS-CoV-2 variants developed which mostly were characterized by
72 mutations in the Spike protein but also within the Nucleocapsid protein.²⁻⁵ Variants showing a
73 decrease in the effectiveness of available diagnostic tests among other criteria are termed Variants of
74 Concern (VOC) by the WHO.⁶ To date the WHO has listed 5 VOCs, namely: B.1.1.7 (alpha),
75 B.1.351 (beta), P.1 (gamma), B.1.617.2 (delta) and the currently prevailing B.1.1.529 (Omicron).⁶
76 For Omicron several sub-lineages have been identified with BA.5 being the currently dominant one
77 in Europe.³

78 The clinical presentation of Covid-19 ranges from asymptomatic to prolonged illness requiring
79 intensive care treatment and death.^{7,8} As SARS-CoV-2 can be transmitted by symptomatic as well as
80 asymptomatic persons the identification of infectious carriers is crucial to contain Covid-19 by means
81 of contact tracing and isolation of infectious patients.⁸ This requires effective testing and an early
82 diagnosis of Covid-19. Detection of acute SARS-CoV-2 infection can be achieved by direct testing
83 including nucleic acid amplification tests (NAATs) or through rapid antigen tests (RATs). NAATs
84 identify viral RNA in specimens from the respiratory tract while RATs recognize viral proteins,
85 mostly the Nucleocapsid protein.⁹ To date NAAT-based assays such as reverse transcription-
86 polymerase chain reaction (RT-PCR) are the gold standard in detecting acute SARS-CoV-2 infection.
87 RATs are widely employed as well as they can be conducted at the point of care, provide fast results
88 within 15-30 minutes, and can be used for self-testing. Positive RAT results need to be verified by
89 RT-PCR testing.¹⁰ Indirect tests including assays detecting antibodies against the Spike- or the
90 Nucleocapsid protein are not useful in the diagnosis of acute infection as they only become positive
91 after 3 days and more or may be already positive from an earlier infection (Nucleocapsid- and Spike
92 antibodies) or vaccination (Spike-Antibodies).^{11,12}

93 This study is the extension of the COVAG study originally performed from February 1, 2021, to
94 March 31, 2021. During the first data collection period we saw that the alpha variant decreased the
95 effectiveness of the RATs compared to the wild-type.¹³ As new SARS-CoV-2 variants emerged
96 afterwards, the COVAG study was continued to comprehensively examine two of the most sensitive

- 97 RATs in a real-world, prospective, head-to-head study, placing specific emphasis on clinical
98 characteristics and the presence of SARS-CoV-2 variant genotypes.⁹

99 2. Methods

100 2.1. Setting and Participants

101 This prospective study was conducted at the Corona Test Centre Cannstatter Wasen in Stuttgart,
102 Germany as an extension of the COVAG study.¹³ Individuals scheduled for RT-PCR testing of
103 nasopharyngeal swabs were advised of the study orally and in writing. Participants had to be aged \geq
104 18 years and capable of understanding the nature, significance, and implications of the study.
105 Children and adolescents <18 years of age and patients obviously suffering from clinical conditions
106 requiring emergency hospitalization were excluded. All participants provided written and informed
107 consent. The study was approved by Ethics Committee II (Mannheim) of the University of
108 Heidelberg (reference number 2020-417MF) and the German Institute for Drugs and Medical
109 Devices.

110 We recorded demographic characteristics, reasons for testing, medical history including SARS-CoV-
111 2 vaccination history, clinical symptoms, and vital signs (heart rate, blood pressure, body
112 temperature, and oxygen saturation) and we stratified the reasons for testing into four major
113 categories: participants referred by their primary care physicians, by the Health Department,
114 participants seeking RT-PCR testing to confirm a positive antigen test and participants who received
115 a warning in their digital contact-tracing app (Corona-Warn-App). We grouped the participants based
116 on their Covid-19 vaccination status into non-vaccinated (0 or 1 vaccination), vaccinated (2
117 vaccinations), boosted (3 or more vaccinations) and with unknown vaccination status.

118 In addition to collecting the oro- and nasopharyngeal swabs for RT-PCR testing, we collected two
119 completely independent nasopharyngeal swab specimens to run two commercially available and
120 widely used RATs. The swabs were collected by medically educated personnel of the test center by
121 rotating teams with strict adherence to the instructions issued by the manufacturers. We used the
122 Abbott Panbio™ COVID-19 Ag Rapid Test (Abbott Rapid Diagnostics Jena GmbH, Jena, Germany,
123 www.abbott.com/poct) and the Roche-SD Biosensor SARS-CoV-2 Rapid Antigen Test (identical to
124 SD BIOSENSOR Standard Q COVID-19 Ag, www.sdbiosensor.com; Roche Diagnostics;
125 Mannheim, Germany, www.roche.com). We chose those two tests in continuation of our first data
126 collection period and because they were among the most sensitive tests according to a Cochrane
127 analysis.^{13,14}

128 Hereafter, we refer to the tests as Abbott-RAT and Roche-RAT, respectively. We randomly assigned
129 the participants to three sampling groups according to the sequence of collecting the nasopharyngeal
130 swabs (group 1: RT-PCR, RAT-Roche, RAT-Abbott; group 2: RAT-Roche, RAT-Abbott, RT-PCR;

131 and group 3: RAT-Abbott, RT-PCR, RAT-Roche) to reduce bias based on the order of test
132 performance.

133

134 **2.2. Analytical procedures**

135 Both the Abbott-RAT and the Roche-RAT were carried out by medically educated staff according to
136 the manufacturers' instructions on-site at the Corona Test Centre, immediately after sampling the
137 nasopharyngeal swabs. The nasopharyngeal swabs for real-time RT-PCR (rRT-PCR) testing were
138 placed in 2 ml of a phosphate-buffered saline solution (ISOTON™ II Diluent, Becton Dickinson,
139 Galway, Ireland) and delivered to the SYNLAB Medical Care Centre Leinfelden-Echterdingen. This
140 ensured that the performers of the RATs were unaware of the RT-PCR-results.

141 SARS-CoV-2 RNA was extracted from the nasopharyngeal swab samples and purified using the
142 PurePrep Pathogens kit and a PurePrep 96 instrument (Molgen, Veenendaal, the Netherlands) within
143 6 h after sampling to limit degradation. The integrity of the RNA was monitored by co-amplification
144 of a control RNA included in the solution for the lysis of the swabs. In cases in which neither SARS-
145 CoV-2 RNA nor the control RNA were detected, the RNA preparation was repeated. The rRT-PCR
146 assay was performed using either the RIDA®GENE SARS-CoV-2 test kit (R-Biopharm, Darmstadt,
147 Germany) or the Allplex SARS-CoV2 (Seegene, Seoul, Korea) or the Virella SARS-CoV-2 seqc
148 (Gerbion, Kornwestheim, Germany) on the CFX96 Touch Real-Time PCR detection device (Bio-
149 Rad, Feldkirchen, Germany) or the CFX-96 IVD Real-Time PCR detection device (Bio-Rad,
150 Feldkirchen, Germany) according to the manufacturers' instructions. The RIDA®GENE SARS-CoV-
151 2 test kit targets the SARS-CoV-2 envelope (E) gene, the Allplex SARS-CoV2 targets the N-gene, S-
152 gene/RdRP and the E-gene (pan Sarbecovirus) and the Virella Seqc SARS-CoV2 targets the RdRp/S-
153 gene and the E-gene (pan Sarbecovirus). Samples producing a cycle threshold (Ct) ≤ 35 were
154 considered positive by RT-PCR.

155 We screened RT-PCR-positive samples with a Ct ≤ 32 for SARS-CoV-2 variants of concern (VOC).
156 Until November 8th 2021 this analysis was performed at SYNLAB Medical Care Center Leinfelden-
157 Echterdingen using the Kits Seegene Allplex Variant I (Seegene, Seoul, Korea) and Virella SARS-
158 CoV2 Mut 3 (Gerbion, Kornwestheim, Germany) according to the supplier's instructions. Afterwards
159 the VOC analysis was performed at SYNLAB Medical Care Center Weiden using the Novaplex
160 SARS-CoV-2 Variants I Assay, Novaplex SARS-CoV-2 Variants IV Assay and Novaplex SARS-
161 CoV-2 Variants VII Assay (Seegene, Seoul, Korea) according to the supplier's instructions.

162 Samples were screened for B.1.617.2 (delta), B.1.617.2.1 (delta plus), B.1.1.529 / BA.1 (omicron)
163 and BA.2 (omicron stealth). Samples with positive results for L452R and P681R and absence of
164 K417N were assigned to the delta variant. Positive results for L452R, P681R and K417N were
165 considered as Delta plus. Presence of N501Y, E484A and HV69/70del were considered as Omikron
166 BA.1 and occurrence of N501Y, E484A with absence of HV69/70del as Omikron BA.2.

167

168 Additionally, 378 RT-PCR-positive samples with a $Ct \leq 30$ were sequenced in April and Mai, 2022
169 at the SYNLAB Medical Care Center Weiden and SYNLAB Medical Care Center Mannheim using
170 the Illumina COVIDSeq Test according to the supplier's instructions. 98 SARS-CoV-2 amplicons
171 were sequenced for each sample. This Whole-Genome-Sequencing (WGS) approach was performed
172 using the NextSeq 500/550/550Dx (Illumina, San Diego, USA) and NovaSeq 6000 systems
173 (Illumina, San Diego, USA). The obtained sequencing reads of RNA libraries, prepared using the
174 ARTIC v3 gene assay panel (Illumina COVIDSeq Test, Illumina, San Diego, USA), were analyzed
175 with the DRAGEN COVID Pipeline (Illumina, San Diego, USA). Third-party software applications
176 Pangolin (version 4.0.6/UsHER Covid-Pipeline_1.1.0) and NextClade (version 1.11.0) were used for
177 lineage and clade determination. Only samples with $\geq 95\%$ genome coverage (% of non-N bases)
178 were statistically processed.

179

180 **2.3. Statistical Analysis**

181 Continuous data are presented as means, standard deviations (SD), medians, and 25th and 75th
182 percentiles. Categorical data are presented as absolute numbers and percentages (Table 1).

183 In our analysis, the performance indicators for the two RATs in relation to RT-PCR (chosen as the
184 gold standard for having COVID-19) are given by sensitivity, specificity, positive predictive value
185 (PPV), negative predictive value (NPV), and diagnostic efficacy (number of correct test results
186 divided by the total number of test results).

187 In Table 2, the p-values apply to two-sided testing of the null hypothesis that the difference between
188 the Abbott-RAT and the Roche-RAT performance indicators is equal to zero. The probability
189 densities underlying the two-sided testing are estimated by means of 5000 bootstrap iterations.

190 The risk of having COVID-19 according to baseline anthropometric and anamnestic characteristics
191 was expressed in terms of crude odds ratios (ORs) and ORs adjusted for age and sex as calculated by
192 logistic regression (Supplementary table 1).

193 We also visualized the sensitivities of both RDTs relative to the rRT-PCR-derived Ct values (Figure
194 2) and the PPVs and NPVs according to hypothetical disease prevalence rates in the range of 0-0.05
195 (Figure 3). To compare the PPV and NPV of the RDTs with standardized criteria on performance, we
196 also used the following hypothetical sensitivity and specificity levels (tiers 1-3) recommended by
197 Kost et al. (34): tier 1, 90%, 95%; tier 2, 95%, 97.5%; and tier 3, 100%, $\geq 99\%$ (Figure 3).

198

199 Finally, we investigated whether the sensitivities of the two RDTs were related to the reason for
200 testing, comorbidities, clinical symptoms, vital signs, or SARS-CoV-2 genotypes using univariate
201 (Table 2) and multivariate logistic regression (Table 3).

202 The statistical tests were two-sided and $P < 0.05$ was considered significant. The analyses were carried
203 out using R v4.0.2 (<http://www.r-project.org>).

204

205 **3. Results**

206 **3.1 Clinical characteristics of Participants**

207 The extension of the COVAG study was conducted from October 20, 2021 to March 18, 2022.
208 Figure 1 shows the data collection period and the emergence of variants framed within the course of
209 the COVID-19 pandemic in Germany. A total of 1508 persons agreed to participate in this study. 21
210 persons were disregarded from further evaluation because at least one of the three tests was not
211 available. This resulted in 1487 persons enrolled in the COVAG Extension study (Figure 2,
212 Supplementary table 1) including 801 (53.9%) women, 685 (46.1%) men and one diverse person
213 (0.1%). Adverse effects from performing any of the tests were not experienced.

214

215 Within the period of data collection, self-testing with RATs and RT-PCR confirmation in the case of
216 a positive RAT was performed very frequently in Germany which in many participants who already
217 had a positive self-test beforehand. To reduce selection bias, we excluded these 591 (39.7%)

218 participants from the further analyses (Figure 2). 888 participants were tested for other reasons.
219 Those included a warning by the Corona-Warn-App in 419 (28.2%) participants, a referral from the
220 health department in 236 (15.9%) participants, and a referral from the primary care physician in 233
221 (15.7%) participants. For 8 (0.5%) participants no information regarding the reason for testing was
222 available (Table 1). The anthropometric and anamnestic characteristics of all 1487 participants can be
223 found in Supplementary table 1. Further data analysis was performed for the 888 participants with
224 reasons for testing other than to confirm a positive RAT.

225 Of 888 participants, 497 (56%) were women and 390 (43.9%) were men, one person (0.1%) is
226 assigned neither to women nor to men. 665 (74.9%) participants self-reported having no
227 comorbidities, while 223 (25.1%) reported having any comorbidities. The most common
228 comorbidities were hypertension (9.5%) and dyslipoproteinemia (4.7%). Other comorbidities were
229 low in frequency. 101 (11.4%) participants self-reported having had a previous Covid-19 infection
230 (Table 1).

231 98 (11.0%) participants are non-vaccinated (0 or 1 vaccination against Covid 19), 321 (36.2%)
232 participants are 'vaccinated' (2 vaccinations against Covid 19), 463 participants (52.1%) have
233 received a booster vaccination (3 or more vaccinations against Covid 19). For six persons (0.7%), the
234 vaccination status is unknown.

235 447 (50.3%) participants reported having clinical symptoms while 441 (49.7%) reported none. The
236 most common symptoms were malaise, cough, headache, and musculoskeletal pain at frequencies of
237 36.6 %, 30.3%, 30.0%, and 16.3%, respectively (Table 1).

238 188 (21.2%) participants were tested positive for SARS-CoV-2 by RT-PCR. 126 (14.2%) were tested
239 positive by the Abbott-RAT and 128 (14.4%) by the Roche-RAT. 125 (14.1%) samples had a Ct
240 value ≤ 25 , 16 (1.8%) a Ct value 25-30, 47 (5.3%) ≥ 30 . 155 (17.5%) RT-PCR samples had a Ct value
241 ≤ 32 . 52 RT-PCR positive samples with a Ct value ≤ 32 could not be examined for variants. Of the
242 remaining 103 samples, the Omicron variant was found in 41 and the Delta variant was found in 62.

243

244

245 3.2 Diagnostic performance of RATs

246 *Sensitivity.* The Abbott-RAT and the Roche-RAT had overall sensitivities of 65.4% (95% CI 60.7-
247 70.2%) and 67.0% (95% CI 62.4-71.8%) respectively (Table 2). The sensitivities of both RATs were
248 significantly associated with the Ct-value derived from RT-PCR (Figure 3A).

249 The Abbott-RAT and Roche-RAT did not show a significant difference in sensitivity ($p=0.2091$;
250 Table 2). Due to higher power in the total study cohort ($n=1487$) the Roche-RAT had a significantly
251 higher sensitivity than the Abbott-RAT ($p=0.0093$, Supplementary table 2). Among participants
252 seeking testing due to a referral by their primary care physician, the sensitivities for the Abbott-RAT
253 and Roche-RAT were 83.5% and 84.8%, for participants with a referral by the health department
254 they were 54.6% and 57.6% and following a warning by their Corona-Warn-App the sensitivities
255 were 48.8% for both tests (Table 2), respectively. In the participants excluded because they were
256 tested to confirm a positive antigen test the sensitivities of the Abbott-RAT and the Roche-RAT were
257 93.0% and 94.5%.

258 Participants with at least one comorbidity showed lower sensitivities (49.1% and 52.8%, Abbott-
259 RAT and Roche-RAT, respectively) than those with no comorbidities (71.9% and 72.6%, Abbott-
260 RAT and Roche-RAT, respectively; Table 2). This finding did not apply to individual comorbidities
261 besides previous Covid-19. Participants with previous Covid-19 showed significantly lower
262 sensitivities of only 26.7% for both RATs (OR 0.12 (95%CI: 0.05,0.3), $p<0.0001$). This finding is
263 attributable to Ct values being markedly higher (Median 31.2) in patients with previous Covid-19 and
264 not consistent anymore when adjusted for the Ct value (Table 3).

265 For participants without previous Covid-19, significantly higher sensitivities (72.8% and 74.7%,
266 Abbott-RAT and Roche-RAT, respectively) were found in line with markedly lower Ct values
267 (Median 19.2).

268 In symptomatic participants, the sensitivities were significantly higher (76.0% and 77.4%, Abbott-
269 RAT and Roche-RAT, respectively) than in asymptomatic participants (28.6% and 31.0%, Abbott-
270 RAT and Roche-RAT, respectively). This finding is in line with Ct-values being lower in
271 symptomatic patients than in asymptomatic patients (Ct Median 18.7 vs. 30.8, Table 2).

272 We further analyzed the diagnostic performance of RATs according to the vaccination status. The
273 sensitivities of the RATs in non-vaccinated participants (0 or 1 vaccination) were 64.9% and 67.7%
274 for Abbott-RAT and Roche-RAT, respectively. For participants with two vaccinations, the

275 sensitivities were 59.4% and 60.9%. For participants with at least one booster vaccination, we find
276 sensitivities equal to 70.6% for both RATs.

277 We also investigated whether the SARS-CoV-2 variants Delta and Omicron affected the sensitivity
278 of the RATs. Both variants had similar sensitivities compared to the wild-type from the first wave of
279 the Covag study. Compared to the alpha variant the alpha variant had significantly lower sensitivities
280 than the wild-type, delta and omicron. (Figure 4).¹³

281 To firmly establish independent predictors of sensitivity, we calculated ORs for having a positive
282 RAT according to subgroups by multivariate logistic regression (Table 3). Covariables were age, sex,
283 Ct value, reason for testing, presence or absence of any comorbidity and previous Covid-19, Covid-
284 19 vaccination status, presence or absence of any clinical symptom, and the SARS-CoV-2 genotype.
285 As expected, Ct values were strongly associated with the sensitivities of both tests. The sensitivities
286 of the Abbott-RAT and Roche-RAT were lower in participants who sought testing due to a warning
287 in the Corona Warn App.

288 When excluding the Ct value from the multivariate logistic regression symptomatic participants were
289 detected with a significantly higher sensitivity than asymptomatic participants (Abbott-RAT: OR
290 4.35, $p=0.0081$; Roche-RAT: OR 3.46, $p=0.0216$). However, when adjusting for the Ct value this
291 finding was not significant anymore (Table 3). The vaccination status was not associated with a
292 change in sensitivity of the RATs.

293 As the Ct value is the strongest predictor for the sensitivity of the RATs, we calculated the sensitivity
294 of the RATs separately for different Ct values. For a Ct value ≤ 25 the sensitivities were 95.2% and
295 96.0% for the Abbott-RAT and the Roche-RAT, respectively (Table 4). For a Ct value of 25-30 both
296 RATs had a sensitivity of 18.8%. For a Ct value of 30-32, the sensitivities were 0.0% and 7.1%
297 respectively, for Ct values ≥ 32 the sensitivities were 3.0% and 6.0% for Abbott-RAT and Roche-
298 RAT, respectively.

299 Specificity. The specificity exceeded 99% overall and in mostly all participant strata (Table 2,
300 Supplementary table 2).

301 PPV, NPV, and diagnostic performance. The rate of true negatives in our study cohort ($n=888$) was
302 697 of 700 (99.6%) and 698 of 700 (99.7%), the rate of false negatives was 65 of 188 (34.6%) and 62
303 of 188 (33.0%) for the Abbott-RAT and the Roche-RAT, respectively. The rate of true positives was

304 123 of 188 (65.4%) and 126 of 700 (67%). The rate for false positives was 3 of 700 (0.4%) and 2 of
305 700 (0.3%) for Abbott-RAT and Roche-RAT, respectively.

306 When also including the participants who already had a positive self-test beforehand (total of
307 $n=1487$) the rate of false negatives decreased to 101 of 704 (14.4%) and 90 of 704 (12.8%) for the
308 Abbott-RAT and the Roche-RAT, respectively. The rate of false positives was also overall very low
309 with 4 of 783 (0.5%) and 2 of 783 (0.3%) for the Abbott-RAT and the Roche-RAT. Of the 591
310 participants who sought RT-PCR testing to confirm a positive self-test, 511 (86.5%) were confirmed
311 positive by RT-PCR while 80 (13.5%) were tested negative by RT-PCR.

312 The SARS-CoV-2 prevalence in our study cohort was 78.8% ($n=888$). At this prevalence the PPV
313 was at 97.6% and 98.4% for Abbott-RAT and Roche-RAT ($n=888$, Table 2). For symptomatic
314 participants the PPV was higher (98.2% and 98.3%, Abbott-RAT and Roche-RAT, respectively) than
315 for asymptomatic participants (92.3% and 96.3%, Abbott-RAT and Roche-RAT, respectively). The
316 NPV was 91.5% and 91.8% for Abbott-RAT and Roche-RAT. The NPV was higher for
317 asymptomatic (93.0% and 93.2%, Abbott-RAT and Roche-RAT, respectively) than for symptomatic
318 participants (89.5% and 90.1%, Abbott-RAT and Roche-RAT, respectively).

319 Because patients with SARS-CoV-2 infections were enriched in our study population compared to
320 the general population, we examined the PPVs and NPVs at assumed prevalence rates up to 0.05
321 (Figure 5). To compare the PPV and NPV of the RATs with standardized performance criteria, we
322 also used the following hypothetical sensitivity and specificity levels (tiers 1-3) recommended by
323 Kost15: tier 1, 90%, 95%; tier 2, 95%, 97.5%; and tier 3, 100%, $\geq 99\%$ (Figure 5). At this prevalence
324 rate, our results suggest a PPV and NPV of 88.9% and 98.2% for Abbott-RAT, and 92.5% and 98.3%
325 for the Roche-RAT, the Roche-RAT displaying a higher PPV than the Abbott-RAT and both scoring
326 higher than the hypothetical tiers 1 through 3, reflecting increases in NPV in the order of Abbott-
327 RAT < Roche-RAT < tier 1 < tier 2 < tier 3. The NPVs ranged in the order of tier 3 > tier 2 > tier 1 >
328 Roche-RAT > Abbott-RAT.

329 4. Discussion

330 This study is an extension of the COVAG study which is one of the largest prospective, real-world
331 evaluations of RATs to date.¹³ We compared two of the most sensitive RATs provided by Abbott
332 Diagnostics and Roche Diagnostics, especially in the light of newly emerged variants.⁹ We found
333 that the sensitivities of RATs for asymptomatic patients was as low as 30%. We found that the
334 Omicron and Delta variant were detected with not significantly different sensitivities compared to the
335 wild-type at Ct values >25. 13

336 In contrast to the first wave of our study there was no significant difference in sensitivity between the
337 Abbott-RAT and Roche-RAT.¹³ However, with an extended sample size (n=1487) after including
338 participants seeking RT-PCR testing to confirm a positive antigen test, the Roche-RAT had a
339 significantly higher sensitivity than the Abbott-RAT (p=0.0093; Supplementary table 2), attributable
340 to the participants with an age \leq median. This finding is in good agreement with the results of the
341 first wave of our study.

342 The sensitivities were substantially higher among participants referred by their primary care
343 physician (84-85 %, Table 2). As primary care physicians refer patients to RT-PCR testing based on
344 their clinical presentation and history, the pretest probability is higher and patients with higher
345 symptom burden sent for testing, also reflected by lower Ct values in these participants. This shows
346 that the sensitivity of the RATs can be increased by considering the clinical background. The PPVs
347 of RATs was overall very good (88-92%). Compared to the tiers recommend by Kost et. al the NPV
348 occur to be lower than the recommend values of tier 1-3. However, due to the smallness of the
349 discrepancies between the measured NPVs and the recommended NPV ranges (<2%) and the small
350 number of false positives, the last statement made about the NPVs should be taken with caution.

351 4.1. Diagnostic performance of the RATs

352 The WHO formulated minimum performance requirements of $\geq 80\%$ sensitivity and $\geq 97\%$
353 specificity for RATs.¹⁶ The European Centre for Disease Prevention and Control (ECDC) agreed to
354 the performance requirements set by the WHO.¹⁷ In our study both RATs did not meet the sensitivity
355 performance requirements while meeting the specificity requirements (Abbott-RAT: sensitivity
356 65.4%, specificity 99.6%; Roche-RAT: sensitivity 67.0%, specificity 99.7%). Similar results were
357 reported by a Cochrane Analysis which reported sensitivities of 56.7% (95% CI 44.3-68.3%) and
358 64.4% (95% CI 52.2-75.0%) for the Abbott-RAT and the Roche-RAT, respectively.⁹ In a large

359 comparative in vitro evaluation of 122 RATs reported the Paul-Ehrlich-Institut (PEI), the overall
360 sensitivity of the Abbott-RAT and the Roche-RAT were 64.0% and 46.0%, respectively.¹⁸ While the
361 Abbott-RAT showed a comparable sensitivity of 65.4% in our study, the Roche-RAT yielded a better
362 sensitivity of 67.0%. However, also in the study by the PEI both RATs failed to meet the sensitivity
363 requirement set by the WHO. This is in large contrast to the sensitivities of 97.6% and 95.5%,
364 respectively, reported by the providers Abbott and Roche. for samples with Ct values ≤ 30 .^{19,20}

365 During our study comparable sensitivities (95.2% and 96% for Abbott-RAT and Roche-RAT,
366 respectively) were reported only for Ct values ≤ 25 . For Ct values of 25-30 the sensitivities were only
367 18.8% for both tests.

368 The RATs' performance strongly relates to Ct values. The study by the Paul-Ehrlich-Institut showed
369 sensitivities for the Abbott-RAT of 100% for Ct-values ≤ 25 , 60.9% for Ct values between 25-30 and
370 0% for Ct values ≥ 30 .¹⁸ The Roche-RAT in comparison yielded a sensitivity of 88.9% for Ct values
371 ≤ 25 , 30.4% for Ct values between 25-30 and also 0% for Ct values ≥ 30 .¹⁸ Evidently thus, the
372 performance of the RATs in our study is worse than in the in vitro study by the Paul-Ehrlich-Institut ,
373 suggesting that challengeable information will only be obtained under real world conditions. This
374 notwithstanding the common denominator of the results fom Paul-Ehrlich-Institut and of ours is that
375 the performance requirements are only met for samples with a Ct ≤ 25 . Hence, patients with a high
376 viral load are well detected while patients with a lower viral load are missed.²¹

377 An important clinical distinction is whether symptoms are present or not. The sensitivity of the RATs
378 is markedly lower for asymptomatic than for symptomatic patients. With a sensitivity of around 30%,
379 asymptomatic and infected patients were detected at very low sensitivity in our study. Symptomatic
380 patients on the other hand are detected with a sensitivity of around 77%. A Cochrane analysis by
381 Dinnes et al. reported similar results for symptomatic (Abbott-RAT: 74.8%; Roche-RAT: 78.8%) and
382 higher results for asymptomatic (Abbott-RAT: 56.9%; Roche-RAT: 59.4%) patients compared to our
383 study.⁹ Although slightly below the performance requirements of the WHO RATs may be considered
384 useful in symptomatic patients while they are not in asymptomatic patients. These differences in
385 sensitivity are clearly attributable to the lower Ct values of symptomatic patients. In Germany RATs
386 have been used for screening of asymptomatic persons.¹⁰ Yet, in these patients RATs are clearly
387 insufficient for screening.

388 The RNA viral load determined by RT-PCR is only a proxy for the infectiousness of patients as also
389 non-infectious viral RNA is detected by RT-PCR. To reliably determine the infectiousness of a

390 patient, viral growth can be examined in culture. In a study from the UK, contacts of SARS-CoV-2
391 infected patients were recruited, and RT-PCR and virus culture were performed daily. Additionally, a
392 RAT different from the ones used in our study was performed in RT-PCR positive samples as well as
393 in samples one day before and after a positive RT-PCR. The sensitivity of the RATs was higher for
394 samples with positive viral cultures (79%) than for samples with only positive RT-PCR (47%).
395 Positive viral cultures were detected for a median of 5 days (IQR 3-7 days) and the peak viral load
396 determined by viral cultures and RT-PCR was at a median of 3 days after symptom onset (IQR 3-5/6
397 days). Interestingly the sensitivity of the RATs was lower before and during the peak viral load
398 (sensitivity: 67%) than after the peak viral load (sensitivity: 92%).²² This shows that RATs have
399 reduced sensitivity during the beginning of infection possibly leading to delayed diagnosis.²² In a
400 study from Germany the Roche-RAT was compared to RT-PCR and viral culture. Although the
401 Roche-RAT reached a sensitivity of only 42.8%, none of the samples with positive viral cultures was
402 missed.²³ Hence and accordance to the current study, RATs appear to have a low overall sensitivity,
403 while highly infectious participants may reliably be detected.

404 The specificity of the RATs was overall very good and met the specificity requirements of the WHO
405 and ECDC.^{16,17,24}

406 **4.2. Influence of the SARS-CoV-2 genotype on the diagnostic performance of RATs**

407 During the first data collection period from February 1 to March 31, 2021, the dominant variants
408 were the wild-type and the alpha variant. The sensitivities of the RATs for the alpha variant were
409 significantly lower than for the wild-type also when adjusted for the Ct-value.¹³ In the current wave
410 of our study ((October 20, 2021 to March 18, 2022), the prevailing variants were Delta followed by
411 Omicron. Omicron was detected with a high sensitivity of 92-94%, while Delta was detected with a
412 lower sensitivity of 80%. This difference can solely be explained by the lower Ct values of Omicron
413 compared to Delta (Median 17.6, IQR 15.7-19.8 vs. Median 19.6, IQR 16.3-23). Consistently, in a
414 multivariate logistic regression adjusted for the Ct values there was no significant difference between
415 Omicron and Delta anymore. Also, when compared at set Ct values of ≤ 25 , 25-30, ≥ 30 there was no
416 significant difference in sensitivity for Delta and Omicron, respectively. While it has been argued
417 that that Omicron produces a higher viral load leading to better detection by RATs in general, recent
418 findings do not confirm this assumption.^{25,26} Another study from the USA also found that the
419 sensitivities for Omicron compared to the Delta variant are not significantly different.²⁷

420 We further examined the sensitivities for Omicron and Delta compared to the wild-type data coming
421 from the first data collection period.

422 **4.3. Influence of the Covid-19 vaccination and previous infection on the diagnostic** 423 **performance of RATs**

424 For patients with previous Covid-19 the sensitivities for Abbott-RAT and Roche-RAT were very low
425 (26.7%). These low sensitivities are attributable to the high Ct values in these patients (Median 30,
426 IQR 25-33). This is plausible because patients with a previous Covid-19 infection may have lower
427 viral loads due to mucous IgA built in response to the previous infection.²⁹ There was no significant
428 difference in the sensitivities between vaccinated and unvaccinated participants (65-66% vs. 66-70%,
429 Table 2). , perhaps since mucous IgA is formed to a lesser extent after vaccination.³⁰ This could
430 explain why the vaccination status does not seem to influence the sensitivity of RATs, while a
431 previous Covid-19 infection could. Another explanation would be that after vaccination antibodies
432 are formed only against the Spike protein whereas after a previous infection antibodies against the
433 Spike protein and the Nucleocapsid protein are formed.³¹ As RATs detect the Nucleocapsid antigen
434 Nucleocapsid antibodies could reduce available antigens for detection.

435 **4.4 Limitations**

436 Among the limitations of this study is that the reference method RT-PCR does not indicate the
437 infectiousness of patients, because RT-PCR can also detect non-viable virus particles, also there is a
438 certain correlation between the Ct value and infectivity.³²

439 Furthermore, we performed RATs once only and not in series. Serial testing for SARS-CoV-2 with
440 RATs may substantially increase their diagnostic performance.³³

441 **4.5 Conclusions**

442 The diagnostic performance of RATs is highly associated with the viral load. The sensitivity of RATs
443 is substantially higher in symptomatic than in asymptomatic patients and in patients referred by
444 primary care physicians compared to other reasons for testing. Hence, RATs are significantly more
445 useful in a clinical setting than for screening purposes. Our study does not suggest that the
446 vaccination status influences the sensitivity of RATs.

447

448 **5. Conflict of Interest**

449 CW, HB, AS, NL, EW, MR, and WM were employed by SYNLAB Holding Germany GmbH or its
450 regional subsidiaries. AD is the owner of Company Dr. Dressel Consulting.

451 The remaining authors declare that the research was conducted in the absence of any commercial or
452 financial relationships that could be construed as a potential conflict of interest.

453 **6. Author Contributions**

454 WM designed the study. CW, AS, HB, NL and H-JW collected the data. AD performed the statistical
455 analysis. EW, AS, HB, NL surveyed the laboratory analyses. CW wrote the manuscript. All authors
456 validated, reviewed, and edited the manuscript.

457 **7. Funding**

458 The costs of the study were defrayed by SYNLAB Holding Deutschland GmbH. The management
459 had no role in writing of the report or the decision to submit for publication. There was no financial
460 support to SYNLAB Holding Deutschland GmbH from the manufacturers of the assays used in this
461 evaluation and there has been no other financial support for this work that could have influenced its
462 outcome.

463 **8. Acknowledgments**

464 We thank the participants for joining in free of remuneration. We thank Katja Pöhl, CEO, SYNLAB
465 MVZ Leinfelden-Echterdingen and Christoph Mahnke, CEO SYNLAB Holding Deutschland GmbH,
466 who supported the study. We thank all study personel, especially Manuel Kraft, Ali Hussein,
467 Alexander Ignatenko, Brigitte Schwandt, Orhan Bunjaku and Rosa Oberhauser for carrying out the
468 RATs and documenting the participants at the Corona Test Center Cannstatter Wasen, Stuttgart.

469 **9. Data Availability Statement**

470 Data will be made available to researchers upon justified request and formal agreement to make sure
471 that rules of good scientific practice are obeyed, and that credit is given to the people who have been
472 in charge of the design and the organization of the study. Interested researchers are invited to address
473 their request or proposal to WM (winfried.maerz@synlab.com). The authors confirm that they
474 accessed and validated these data and that all other researchers can access the data in the same
475 manner the authors did.

476 10. References

- 477 1. World Health Organization. WHO characterizes COVID-19 as a pandemic. Updated 31 July
478 2020. Accessed 24.09.2022, [https://www.who.int/emergencies/diseases/novel-coronavirus-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen)
479 [2019/events-as-they-happen](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen)
- 480 2. Zhang Y, Zhang H, Zhang W. SARS-CoV-2 variants, immune escape, and countermeasures.
481 *Front Med.* 2022;16(2):196-207. doi:10.1007/s11684-021-0906-x
- 482 3. SARS-CoV-2 variants of concern as of 22 September 2022. European Centre for Disease
483 Prevention and Control (ECDC). Accessed 26.09.2022, [https://www.ecdc.europa.eu/en/covid-](https://www.ecdc.europa.eu/en/covid-19/variants-concern)
484 [19/variants-concern](https://www.ecdc.europa.eu/en/covid-19/variants-concern)
- 485 4. Wu H, Xing N, Meng K, et al. Nucleocapsid mutations R203K/G204R increase the
486 infectivity, fitness, and virulence of SARS-CoV-2. *Cell Host Microbe.* 2021;29(12):1788-1801.e6.
487 doi:10.1016/j.chom.2021.11.005
- 488 5. Osterman A, Badell I, Basara E, et al. Impaired detection of omicron by SARS-CoV-2 rapid
489 antigen tests. *Med Microbiol Immunol.* 2022;211(2-3):105-117. doi:10.1007/s00430-022-00730-z
- 490 6. World Health Organization. Tracking SARS-CoV-2 variants. Accessed 26.09.2022,
491 <https://www.who.int/activities/tracking-SARS-CoV-2-variants>
- 492 7. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients
493 with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* 2020;395(10229):1054-1062.
494 doi:10.1016/s0140-6736(20)30566-3
- 495 8. Glenet M, Lebreil AL, Heng L, N'Guyen Y, Meyer I, Andreoletti L. Asymptomatic COVID-
496 19 adult outpatients identified as significant viable SARS-CoV-2 shedders. *Sci Rep.* 2021;11(1).
497 doi:10.1038/s41598-021-00142-8
- 498 9. Dinnes J, Sharma P, Berhane S, et al. Rapid, point-of-care antigen tests for diagnosis of
499 SARS-CoV-2 infection. *Cochrane Libr.* 2022;2022(7). doi:10.1002/14651858.cd013705.pub3
- 500 10. Bundesministerium für Gesundheit. Fragen und Antworten zu COVID-19 Tests.
501 Bundesministerium für Gesundheit. Accessed 14.12.2022,
502 [https://www.bundesgesundheitsministerium.de/coronavirus/nationale-teststrategie/faq-covid-19-](https://www.bundesgesundheitsministerium.de/coronavirus/nationale-teststrategie/faq-covid-19-tests.html)
503 [tests.html](https://www.bundesgesundheitsministerium.de/coronavirus/nationale-teststrategie/faq-covid-19-tests.html)
- 504 11. Deeks JJ, Dinnes J, Takwoingi Y, et al. Antibody tests for identification of current and past
505 infection with SARS-CoV-2. *Cochrane Libr.* 2020;2020(6). doi:10.1002/14651858.cd013652
- 506 12. Stocking C, de Miguel L, Suteu G, et al. Evaluation of five widely used serologic assays for
507 antibodies to SARS-CoV-2. *Diagn Microbiol Infect Dis.* 2022;102(2):115587.
508 doi:10.1016/j.diagmicrobio.2021.115587
- 509 13. Wertenaue C, Brenner Michael G, Dressel A, et al. Diagnostic performance of rapid antigen
510 testing for SARS-CoV-2: The COVid-19 AntiGen (COVAG) study. *Front Med (Lausanne).* 2022;9.
511 doi:10.3389/fmed.2022.774550
- 512 14. Dinnes J, Deeks JJ, Berhane S, et al. Rapid, point-of-care antigen tests for diagnosis of
513 SARS-CoV-2 infection. *Cochrane Libr.* 2021;2022(7). doi:10.1002/14651858.cd013705.pub2
- 514 15. Kost GJ. The impact of increasing disease prevalence, false omissions, and diagnostic
515 uncertainty on Coronavirus disease 2019 (COVID-19) test performance. *Arch Pathol Lab Med.*
516 2021;145(7):797-813. doi:10.5858/arpa.2020-0716-sa

- 517 16. World Health Organization. *Antigen-detection in the diagnosis of SARS-CoV-2 infection:*
518 *interim guidance, 6 October 2021.* 2021. 2021. <https://apps.who.int/iris/handle/10665/345948>
- 519 17. European Centre for Disease Prevention and Control. *Options for the use of rapid antigen*
520 *detection tests for COVID-19 in the EU/EEA – first update, 26 October 2021.* 2021.
521 [https://www.ecdc.europa.eu/en/publications-data/options-use-rapid-antigen-tests-covid-19-eueea-](https://www.ecdc.europa.eu/en/publications-data/options-use-rapid-antigen-tests-covid-19-eueea-first-update)
522 [first-update](https://www.ecdc.europa.eu/en/publications-data/options-use-rapid-antigen-tests-covid-19-eueea-first-update)
- 523 18. Scheiblauser H, Filomena A, Nitsche A, et al. Comparative sensitivity evaluation for 122 CE-
524 marked rapid diagnostic tests for SARS-CoV-2 antigen, Germany, September 2020 to April 2021.
525 *Euro Surveill.* 2021;26(44). doi:10.2807/1560-7917.es.2021.26.44.2100441
- 526 19. Abbott. PANBIO™ COVID-19 Ag RAPID TEST DEVICE. Accessed 26.10.2022,
527 <https://www.globalpointofcare.abbott/de/product-details/panbio-covid-19-ag-antigen-test.html>
- 528 20. Roche. SARS-CoV-2 Rapid Antigen Test Instructions to Use Accessed 26.10.2022,
529 [https://assets.cwp.roche.com/f/94122/x/074742adcc/packungsbeilage_sars-cov-](https://assets.cwp.roche.com/f/94122/x/074742adcc/packungsbeilage_sars-cov-2rapidantigentest_023_de_202104.pdf)
530 [2rapidantigentest_023_de_202104.pdf](https://assets.cwp.roche.com/f/94122/x/074742adcc/packungsbeilage_sars-cov-2rapidantigentest_023_de_202104.pdf)
- 531 21. Singanayagam A, Patel M, Charlett A, et al. Duration of infectiousness and correlation with
532 RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. *Euro*
533 *Surveill.* 2020;25(32). doi:10.2807/1560-7917.es.2020.25.32.2001483
- 534 22. Hakki S, Zhou J, Jonnerby J, et al. Onset and window of SARS-CoV-2 infectiousness and
535 temporal correlation with symptom onset: a prospective, longitudinal, community cohort study.
536 *Lancet Respir Med.* 2022;10(11):1061-1073. doi:10.1016/s2213-2600(22)00226-0
- 537 23. Korenkov M, Poopalasingam N, Madler M, et al. Evaluation of a rapid antigen test to detect
538 SARS-CoV-2 infection and identify potentially infectious individuals. *J Clin Microbiol.* 2021;59(9).
539 doi:10.1128/jcm.00896-21
- 540 24. World Health Organization. Antigen-detection in the diagnosis of SARS-CoV-2 infection.
541 Interim guidance. 6 October 2021. 2021
- 542 25. Loacker L, Dlaska M, Griesmacher A, Anliker M. Ct values of different SARS CoV2
543 variants: a single center observational study from Innsbruck, Austria. *Clin Chem Lab Med.*
544 2022;60(10):e225-e227. doi:10.1515/cclm-2022-0542
- 545 26. Yuasa S, Nakajima J, Takatsuki Y, et al. Viral load of SARS-CoV-2 Omicron is not high
546 despite its high infectivity. *J Med Virol.* 2022;94(11):5543-5546. doi:10.1002/jmv.27974
- 547 27. Soni A, Herbert C, Filippaios A, et al. Comparison of rapid antigen tests' performance
548 between delta and omicron variants of SARS-CoV-2: A secondary analysis from a serial home self-
549 testing study. *Ann Intern Med.* 2022;175(12):1685-1692. doi:10.7326/m22-0760
- 550 28. Wagenhäuser I, Knies K, Hofmann D, et al. Virus variant-specific clinical performance of
551 SARS coronavirus two rapid antigen tests in point-of-care use, from November 2020 to January
552 2022. *Clin Microbiol Infect.* 2023;29(2):225-232. doi:10.1016/j.cmi.2022.08.006
- 553 29. Sterlin D, Mathian A, Miyara M, et al. IgA dominates the early neutralizing antibody
554 response to SARS-CoV-2. *Sci Transl Med.* 2021;13(577). doi:10.1126/scitranslmed.abd2223
- 555 30. Sheikh-Mohamed S, Isho B, Chao GYC, et al. Systemic and mucosal IgA responses are
556 variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection
557 against subsequent infection. *Mucosal Immunol.* 2022;15(5):799-808. doi:10.1038/s41385-022-
558 00511-0

559 31. Montague BT, Wipperman MF, Chio E, et al. Elevated serum IgA following vaccination
560 against SARS-CoV-2 in a cohort of high-risk first responders. *Sci Rep.* 2022;12(1).
561 doi:10.1038/s41598-022-19095-7

562 32. Platten M, Hoffmann D, Grosser R, et al. SARS-CoV-2, CT-values, and infectivity—
563 conclusions to be drawn from side observations. *Viruses.* 2021;13(8):1459. doi:10.3390/v13081459

564 33. Wu S, Archuleta S, Ming LS, Somani J, Chye QS, Fisher D. Serial antigen rapid testing in
565 staff of a large acute hospital. *Lancet Infect Dis.* 2022;22(1):14-15. doi:10.1016/s1473-
566 3099(21)00723-4

567

568

569 **Figure Legends**

570 Figure 1: Framing of the COVAG extension study (October 20, 2021, to March 18, 2022) into the
571 time course of the COVID-19 pandemic in Germany. *Abszissa:* calendar week within 2021 and 2022;
572 *bars:* Germany-wide weekly proportions of variants of concern (VOC) in percent.
573 *Blue solid line:* estimated proportion of variant B.1.617.2 (Delta) in the COVAG extension study to
574 Germany (based on logistic regression with the categories ‘Delta’ vs. ‘Omikron’).
575

576 Figure 2: Flowchart illustrating the inclusion of participants into the COVAG Extension study and
577 data analysis.

578

579 Figure 3: Relationships between sensitivities of RDTs vs. rRT-PCR cycle threshold (Ct) values. The
580 solid lines indicate sensitivities, the dotted lines represent the upper, and the lower bounds the
581 corresponding 95% confidence intervals. (A) left: Roche-RDT; right: Abbott-RDT. (B) Sensitivities
582 according to SARS-CoV-2 genotypes. left: Roche-RDT; right: Abbott-RDT; *red:* Delta variant; *blue:*
583 Omikron variant.

584

585 Figure 4: rRT-PCR cycle thresholds (Ct) values on rRT-PCR for SARS-Cov-2 RNA of different
586 variants *versus* sensitivities of the Roche-RDT. The *solid lines* indicate sensitivities, the *dotted lines*
587 represent the upper and the lower bounds the corresponding 95% confidence intervals. *magenta:*
588 Delta; *red:* Omikron; *green:* Alpha; *blue:* WT.

589

590 Figure 5: (A) Prevalence *versus* PPV for tier 1-3 (for hypothetical sensitivities and specificities (Kost
591 et al.)) and both rapid tests. (B Prevalence *versus* NPV for tier 1-3 (for hypothetical sensitivities and
592 specificities (Kost et al.)) and both rapid tests.

Figure 1




Figure 2

Flowchart illustrating the inclusion of participants





Figure 3A

Roche-RAT (delta~red, omikron~blue)



Abbott-RAT (delta~red, omikron~blue)





Figure 3B

Roche-RAT (delta~red, omikron~blue)



Abbott-RAT (delta~red, omikron~blue)




Figure 4




Figure 5A

PPV vs. prevalence




Figure 5B

